New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy

RÉMI ROSIÈRE¹, MICHEL GELBCKE², VÉRONIQUE MATHIEU³, PIERRE VAN ANTWERPEN²,⁴, KARIM AMIGHI¹ and NATHALIE WAUTHOZ¹

¹Laboratory of Pharmaceutics and Biopharmaceuticals, ²Laboratory of Therapeutic Chemistry, ³Laboratory of Cancerology and Experimental Toxicology, ⁴Analytical Platform, Faculty of Pharmacy, Université Libre de Bruxelles (ULB), B-1050 Brussels, Belgium

Received May 6, 2015; Accepted June 22, 2015

DOI: 10.3892/ijo.2015.3092

Abstract. Besides the numerous advantages of a chemotherapy administered by the inhalation route for lung cancer therapy, dry powder for inhalation (DPI) offers many advantages compared to other techniques and seems to be a technique that is well-adapted to an anticancer treatment. DPI formulations were developed using the cytotoxic drug temozolomide and a new folate-grafted self-assembling copolymer, a conjugate of three components, folate-polyethylene glycol-hydrophobically-modified dextran (F-PEG-HMD). F-PEG-HMD was synthesized using carbodiimide-mediated coupling chemistry in three main steps. F-PEG-HMD was characterized by ¹H-NMR, mass spectrometry and thermal analysis. F-PEG-HMD presented a critical micellar concentration in water of 4x10⁻⁷ M. F-PEG-HMD nanomicelles were characterized by a trimodal particle size distribution with Z-average diameter of 83±1 nm in water. Temozolomide-loaded nanomicelles were prepared by solubilization of F-PEG-HMD in the presence of temozolomide. Temozolomide solubility in water was increased in the presence of F-PEG-HMD (2-fold increase in molar solubility) which could potentially lead to increased local concentrations in the tumor site. The temozolomide-loaded F-PEG-HMD nanomicelles were characterized by a Z-average diameter of ~50 to ~60 nm, depending on the F-PEG-HMD concentration used. The nanomicelles were then spray-dried to produce dry powders. Temozolomide remained stable during all the formulation steps, confirmed by similar in vitro anticancer properties for the DPI formulations and a raw temozolomide solution. Two of the developed DPI formulations were characterized by good aerodynamic properties (with a fine particle fraction of up to 50%) and were able to release the F-PEG-HMD nanomicelles quickly in aqueous media. Moreover, in vitro, the two DPI formulations showed wide pulmonary deposition in the lower respiratory tract where adenocarcinomas are more often found. The present study, therefore, shows that F-PEG-HMD-based dry powders for inhalation could constitute an interesting drug delivery system able to release nanomicelles that are useful in adenocarcinomas that overexpress folate receptors.

Introduction

Lung cancer is one of the most frequent types of cancer in the world and remains the most deadly (1). Most lung cancers (~85%) are non-small cell lung cancers (NSCLC), which are mainly represented by adenocarcinomas (~50%) (2). Unlike squamous cell carcinomas (~20%), which are usually located in the bronchi, adenocarcinomas are often found deeper in the lung (2,3). Nowadays, a new updated classification of lung cancers is more appropriate, following the establishment of
a broad global database of cancers (3). Therefore, new histological classifications identifying new targets are provided (2) and allow administration of more personalized treatment to the patient (4). For this purpose, different studies have shown an overexpression of folate receptor (FR), especially FRα, in adenocarcinomas, compared to healthy cells (5-8). In such cases, up to 72% of strongly FR-positive tumors are reported (6).

Conventional or targeted chemotherapies are currently administered through systemic routes. This leads to low, short-term concentration in the tumor site and causes dose-limiting systemic toxicities to the patient. These observations could be partly responsible for the limited 5-year survival rate obtained for lung cancers [18% from 2004 to 2010 in the United States (1)]. Pulmonary delivery could be an interesting alternative for the treatment of lung cancers. Use of this route allows administration of high doses of conventional or targeted chemotherapy directly to the lung tumor site and reduction of systemic distribution and toxicities, significantly enhancing the therapeutic ratio (9). Among approaches for pulmonary delivery, dry powder for inhalation (DPI) offers many advantages for anticancer treatments compared to other techniques (10). DPI-based formulations are in a solid state, which is more stable for long-term storage and better adapted to poorly water-soluble drugs such as conventional cytotoxic chemotherapeutics. Moreover, the DPI devices can deliver high doses and are activated and driven by the patient’s inspiratory flow for a short administration time. They are easily transportable and less expensive, require less maintenance and can be manufactured as disposable inhalers to limit device and environmental contamination in comparison with nebulizers. Much development has been done of DPI formulations for lung cancer therapy, confirming the great interest in this approach (10-13).

Nanotechnology applications in medicine, defined as nanomedicine, have led to a number of applications for cancer imaging or treatment (14,15). Nanocarriers or nanovectors consist of a system composed of drugs, polymeric and/or lipid material that improves biokinetics and biodistribution of these drugs and a ligand that increases the specific cancer cell targeting. Using nanocarrier systems presents many advantages in cancer therapy; this is especially true for pulmonary drug delivery in lung cancer therapy. The advantages include the potential to i) increase drug bioavailability (local or systemic), ii) overcome biological barriers (e.g. mucus, membrane), iii) enhance solubility of the drug, iv) avoid or reduce phagocytosis by alveolar macrophages, v) prolong pulmonary residence time, vi) protect drug from degradation, vii) accumulate drug preferentially into tumors, viii) enhance drug internalization by cells and ix) specifically recognize single cancer cells (16-18). Large numbers of studies on designing nanocarriers for tumor targeting that are delivered by the inhalation route have been described (19-22). However, unlike other types of nanocarriers, self-assembling nanomicelles, in particular polymeric self-assembled micelles contained in a DPI formulation, have not been developed so much (23). This is despite their numerous advantages, such as high in vivo stability, high potential to increase the water solubility of poorly water-soluble drug, and a high ability to be designed for active targeting (24-26). Self-assembled polymers are amphiphilic polymers, i.e. they contain both hydrophilic and hydrophobic moieties, and are able to aggregate spontaneously in aqueous media to form nanomicelles (24-26).

In this context, we have developed DPI formulations composed of a new folate-grafted self-assembling copolymer, F-PEG-HMD, derived from a hydrophobically-modified dextran, which is designed to increase the water solubility of poorly-water-soluble compounds, such as most cytotoxic agents, by micelle solubilization. We chose the poorly water-soluble drug temozolomide (TMZ) (solubility in water ~3 mg/ml). This drug could be a good candidate for the inhalation route in lung cancer therapy and has already been the subject of aerosol development (10,27). TMZ is a prodrug that is activated at physiologic pH to produce a reactive methyldiazonium ion that is able to methylate DNA (28). TMZ induces autophagy (29) followed by late apoptosis (30). Its unique characteristics mean that TMZ is used in the treatment of cancers associated with extremely poor prognoses, such as glioblastomas and melanomas (31). TMZ has also been evaluated in phase II clinical studies for both small cell lung cancer (32) and NSCLC patients (33-35). Moreover, TMZ presents a relatively acceptable safety profile (36), and only rare respiratory adverse reactions have been reported (37).

The aim of the present study was to design and synthesize a new folate-grafted self-assembling copolymer, i.e. F-PEG-HMD, to use it to prepare TMZ-based nanomicelles and to embed the nanomicelles in dry powders for inhalation to allow the nanomicelles to reach the deep lung to combat adenocarcinoma that overexpress FRα.

Materials and methods

Materials. All chemical reagents were of analytical grade and used without further purification. Anhydrous dimethyl sulfoxide (DMSO), N,N′-dicyclohexylcarbodiimide (DCC), 4-(dimethylamino)pyridine (DMAP), triethylamine (TEA), deuterium oxide containing 3-(trimethylsilyl)-1-propanesulfonic acid-d6 sodium salt (DSS-d6), folic acid, N-hydroxysuccinimide (NHS), DMSO-d6, trifluoroacetic acid (TFA), 3-[4,5-dimethylthiazol-2-yl] diphenyltetrazolium bromide (MTT), dichloromethane and ethanol were purchased from Sigma-Aldrich (St. Louis, MO, USA), α-t-butylxycarbonylmino-ω-amino poly (ethylene glycol) (Boc-NH-PEG-NH₂) was purchased from Iris Biotech GmbH (Marktredwitz, Germany). Stearic acid was purchased from Fagron (Waregem, Belgium). Dextran T10 was purchased from Pharmacosmos (Holbaek, Denmark). Temozolomide (TMZ) was purchased from Shilpa Medicare Ltd (Raichur, India). Roswell Park Memorial Institute medium (RPMI) and folate-free RPMI, fetal bovine serum (FBS), penicillin-streptomycin solution, gentamycin solution and trypsin-EDTA solution were purchased from Life Technologies (Merelbeke, Belgium).

Synthesis of folate-polyethylene glycol-hydrophobically-modified dextran (F-PEG-HMD), and synthesis of hydrophobically-modified dextran-succinate (HMD-succinate).

To prepare HMD-succinate, 100 mg of dextran T10 was dissolved in 7 ml of anhydrous DMSO under magnetic stirring. Then 90 mg of stearic acid, 135 mg of DCC and 20 mg of DMAP were added to the DMSO solution and the mixture was...
stirred at 60°C for 24 h. To the DMSO solution, 30 mg of succinic anhydride, 80 µl of TEA and 12 mg of DMAP were added and the mixture was stirred at 40°C overnight. The reaction mixture was dialyzed [molecular weight cut-off (MWCO) = 10 kDa, Spectra/Por; Spectrum Labs, Breda, The Netherlands] against ultrapure water and the dialysate was filtrated to remove the byproduct N,N'-dicyclohexylurea (DCU) and unreacted DCC and stearic acid. The filtrate was finally lyophilized by means of an Epsilon 1-6 freeze-dryer (Martin Christ GmbH, Osterode am Harz, Germany). The HMD-succinate molecular structure was confirmed by proton nuclear magnetic resonance spectroscopy ([H NMR] using a Bruker Avance 300 spectrometer (Bruker Biospin SA, Wissembourg, France) in D2O or in DMSO-d6 at 25°C. [H NMR] (chemical shifts (δ) are given in ppm relative to DSS-d6) δ (ppm): 0.9 (3H, stearate (ST), CH3(CH2)3), 1.3 (28H, ST, CH3(CH2)4H5CH2) and 1.6 (2H, ST, CH2CH2CH2); 2.5 and 2.7 (4H, succinate (SU), OOCCH2CH2COO), 3.3-4.5 (6H, glucose (GLC), C2-6H0), 4.7 (1H, GLC, C1HO), 4.9-5.2 (3H, esterified GLC, C2-4HOCO).

The number of ST chains and of SU groups as a percentage of the total initial hydroxyl group number per HMD-succinate molecule, i.e. the ST-graft ratio (ST-GR) and the SU-graft ratio (SU-GR), respectively, were determined by [H NMR] using the following equations (1) and (2):

\[
\text{ST - GR (%) = } 100 \times \frac{[(\text{CH}_3\text{ST})]}{9 \times [(\text{C1HO}) \text{GLC}]}
\]

\[
\text{SU - GR (%) = } \frac{[(\text{CH}_2\text{CH}_2\text{SU}) \times \text{ST - GR}]}{4 \times [(\text{CH}_3\text{ST})]}
\]

where [(CH3ST)] is the integral of the proton peak of ST at 0.9 ppm, [(CH2CH2SU)] is the integral of the proton peaks of SU at 2.5 and 2.7 ppm and [(C1HO)GLC] is the integral of the proton peak of GLC monomer peak at 4.7 ppm.

**Synthesis of folate-polyethylene glycol (F-PEG).** The carboxylic groups of folic acid were first conjugated with the free amino groups of folic acid using an adaptation of previously reported methods (38,39). Briefly, 1.51 g of folic acid was dissolved in 20 ml of anhydrous DMSO containing 420 µl of TEA by sonication. Then 630 mg of DCC, 350 mg of DMAP were added to this DMSO solution and the mixture was stirred at room temperature in the dark overnight. The precipitated byproduct, DCU, was filtrated and the filtrate was added to 420 µl of TEA in the presence of 210 mg of TEA and 5 mg of DMAP were added to this solution and the mixture was stirred at 40°C for 24 h. The reaction mixture was dialyzed (MWCO = 10 kDa) against ultrapure water in order to remove DMSO, then ultrafiltrated (MWCO = 10 kDa) against a 70% (v/v) ethanol solution. Ethanol was evaporated under vacuum and the resulting aqueous solution was lyophilized. The F-PEG-HMD molecular structure was confirmed by [H NMR] in D2O at 25°C. [H-NMR (D2O) δ (ppm): 0.9 (3H, ST, CH3(CH2)3), 1.3 (28H, ST, CH3(CH2)4H5CH2) and 1.6 (2H, ST, CH2CH2CH2); 2.5 and 2.7 (4H, SU, OOCCH2CH2COO), 3.3-4.5 (6H, GLC, C2-6H0), 4.7 (288H, PEG, CH2O), 4.9-5.2 (3H, esterified GLC, C2-4HOCO), 6.9 (2H, folate, benzene), 7.7 (2H, folate, benzene), 8.8 (1H, folate, pteridin). The folate content value determined by quantitative UV spectroscopy of the conjugate in methanol using the folic acid extinction coefficient ε value of 28,400 m² cm⁻¹ at λmax of 285 nm using an Agilent 8453 UV/Visible Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). [H NMR] (DMSO-d6) δ (ppm): 1.4 (9H, Boc, (CH3)3COCONH), 3.7 (288H, PEG, CH2O), 6.9 (2H, folate, benzene), 7.7 (2H, folate, benzene), 8.8 (1H, folate, pteridin). The folate content value determined by thermogravimetric analysis
Table I. Composition and physicochemical properties of the nanomicelle solutions.

<table>
<thead>
<tr>
<th>Formulations</th>
<th>F-PEG-HMD (mg/ml)</th>
<th>Temozolomide (mg/ml)</th>
<th>Z-average (nm)</th>
<th>PdI</th>
<th>EE (%) (w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F-PEG-HMD</td>
<td>1</td>
<td>/</td>
<td>83±1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.46±0.01&lt;sup&gt;b&lt;/sup&gt;</td>
<td>/</td>
</tr>
<tr>
<td>Empty NS-1</td>
<td>1</td>
<td>/</td>
<td>56.8±0.4&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.43±0.03&lt;sup&gt;c&lt;/sup&gt;</td>
<td>/</td>
</tr>
<tr>
<td>Empty NS-9</td>
<td>9</td>
<td>/</td>
<td>68±1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.43±0.04&lt;sup&gt;c&lt;/sup&gt;</td>
<td>/</td>
</tr>
<tr>
<td>NS-1</td>
<td>1</td>
<td>3.6</td>
<td>50±1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.38±0.02&lt;sup&gt;c&lt;/sup&gt;</td>
<td>6±3</td>
</tr>
<tr>
<td>NS-3</td>
<td>3</td>
<td>4.0</td>
<td>53±1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.37±0.01&lt;sup&gt;c&lt;/sup&gt;</td>
<td>9±2</td>
</tr>
<tr>
<td>NS-5</td>
<td>5</td>
<td>4.8</td>
<td>60±4&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.38±0.02&lt;sup&gt;c&lt;/sup&gt;</td>
<td>9.5±0.7</td>
</tr>
<tr>
<td>NS-9</td>
<td>9</td>
<td>4.9</td>
<td>61±3&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.44±0.07&lt;sup&gt;c&lt;/sup&gt;</td>
<td>8.9±0.8</td>
</tr>
</tbody>
</table>

<sup>a</sup>Polydispersity index. <sup>b</sup>Determined in ultrapure water at 25°C. <sup>c</sup>Determined in a phosphate buffer at pH 5.0 at 25°C. <sup>d</sup>Entrapment efficiency. <sup>e</sup>Results are expressed as mean ± SD (n=3).

(TGA) using a Q500 apparatus (TA Instruments, Zellik, Belgium) and Universal Analysis 2000 version 4.4A software (TA Instruments). The run on ~5 mg of F-PEG-HMD was set from 25 to 300°C at a heating rate of 10°C/min.

The thermal properties of F-PEG-HMD were determined by differential scanning calorimetry (DSC) using a Q2000 differential scanning calorimeter coupled to a refrigerated cooling system (TA Instruments). Results were analyzed using Universal Analysis 2000 version 4.4A software (TA Instruments). Approximately 10 mg of F-PEG-HMD were placed in a Tzero hermetic aluminium pan. The heat run was set from 0 to 190°C at 20°C/min using nitrogen as the blanket gas.

Determination of the critical micellar concentration, and the size and zeta potential of the nanomicelles in water. The critical micellar concentration (CMC), defined as the concentration at which F-PEG-HMD starts to self-assemble and aggregate as a nanomicelle, was determined by dynamic light scattering (DLS) in ultrapure water at 25°C using a Malvern Zetasizer nano ZS (Malvern Instruments, Worcestershire, UK) according to the manufacturer’s instructions. Briefly, F-PEG-HMD solutions were prepared at concentration of 1×10<sup>-4</sup> mg/ml in ultrapure water at room temperature. The intensity of scattered light was measured in triplicate and plotted for each solution. The CMC corresponds to the concentration at which the intensity of scattered light measured increases due to the presence of nanomicelles.

The particle size distribution, the Z-average mean diameter (Z-average) and the polydispersity index (PdI) of the nanomicelles were determined at a concentration of 1 mg/ml F-PEG-HMD in ultrapure water by DLS. The zeta potential was determined by laser Doppler electrophoresis in ultrapure water using the same apparatus as for size measurement. Each parameter was measured in triplicate and the results are expressed as mean ± SD.

Preformulation investigation - micellar solubilization of TMZ. TMZ saturation solubility in the absence (S<sub>sat</sub>) or presence of F-PEG-HMD (1, 5, 10, 15 and 20 mg/ml, corresponding to mean molar concentrations of 0.023, 0.116, 0.232, 0.349 and 0.465 mM, respectively) was determined in a phosphate buffer (20.14 mM) at pH 5.0 (European Pharmacopeia 7.0). Briefly, 1 ml buffer containing F-PEG-HMD and ~7 mg TMZ was prepared and left to dissolve at 50°C in an ultrasonic bath until complete dissolution. The solutions were then placed under mild rotating stirring overnight at room temperature and then centrifuged at 3,000 x g at room temperature using a Heraeus Multifuge XIR centrifuge (Thermo Fisher Scientific, Waltham, MA, USA). The supernatants were then collected and analyzed in terms of TMZ content using the validated HPLC method described by Wauthoz et al (10,27). The total TMZ molar solubility (S<sub>tot</sub>) values were plotted for each molar concentration of the micellar F-PEG-HMD [C<sub>mic</sub>, which corresponds to the concentration of F-PEG-HMD, as CMC is negligible regarding concentrations of F-PEG-HMD (40)]. The slope of the curve corresponds to the molar solubilization capacity (k) value, defined as the number of moles of TMZ that can be solubilized by 1 mol of micellar F-PEG-HMD (40). Each supernatant was analyzed in triplicate and the results are expressed as mean ± SD.

Preparation of dry powders. All manipulation procedures concerning protection of the manipulator and the environment have been previously described by Wauthoz et al (10).

F-PEG-HMD nanomicelle solutions were first prepared by solubilization of F-PEG-HMD in the absence (Empty NS-1 and Empty NS-9) or presence of TMZ (NS-1, NS-3, NS-5 and NS-9) as described in Table I. Briefly, F-PEG-HMD was dissolved with or without TMZ in a phosphate buffer at pH 5.0 (European Pharmacopeia 7.0) at 50°C using an ultrasonic bath. The resulting solutions were cooled at room temperature and then analyzed in terms of size (particle size distribution, Z-average and PdI) and entrapment efficiency (EE). The composition and physicochemical properties of Empty NS-1, Empty NS-9, NS-1, NS-3, NS-5 and NS-9 micellar solutions are presented in Table I. EE is defined as the mass proportion of TMZ entrapped by nanomicelles relative to total TMZ and determined using the following equation (4):

\[
EE(\%) = 100 \times \frac{C_{\text{total TMZ}} - C_{\text{non micellar TMZ}}}{C_{\text{total TMZ}}}
\]
Aerodynamic performance of the dry powders. Dry powders in triplicate. The theoretical compositions of the SD-2.5, SD-7.5, SD-12.5 and SD-22.5 formulations after spray-drying are presented in Table II. The concentration of the dry powder formulations were determined after centrifugal ultrafiltration (Microsep 1 kDa; Pall Life Sciences, Hoegaarden, Belgium). All TMZ contents were determined using the validated HPLC method described elsewhere (10, 27). The percentages of dissolved TMZ were determined by the HPLC method at different times up to 160 min. The 100% TMZ dissolution concentration corresponds to the TMZ concentration at 160 min (n=3).

\[
\begin{align*}
\text{Actual TMZ content}^b &= C_{\text{total TMZ}} - C_{\text{non-micellar TMZ}} \quad \text{where } C_{\text{total TMZ}} \text{ is the total TMZ mass concentration and } C_{\text{non-micellar TMZ}} \text{ is the TMZ mass concentration determined after centrifugal ultrafiltration.}
\end{align*}
\]

Formulations | F-PEG-HMD | Leucine | Mannitol | TMZ | Actual TMZ content$^b$
--- | --- | --- | --- | --- | ---
SD-2.5 | 2.5 | 20 | 68.5 | 9 | 8.4±0.2
SD-7.5 | 7.5 | 20 | 62.5 | 10 | 10.23±0.04
SD-12.5 | 12.5 | 20 | 55.5 | 19.2 | 12.2±0.4
SD-22.5 | 22.5 | 20 | 72.4 | 19.6 | 11.9±0.2

$^a$Temozolomide. $^b$Results are expressed as mean ± SD contents (n=3).

where $C_{\text{total TMZ}}$ is the total TMZ mass concentration and $C_{\text{non-micellar TMZ}}$ is the TMZ mass concentration determined after centrifugal ultrafiltration (Microsep 1 kDa; Pall Life Sciences, Hoegaarden, Belgium). All TMZ contents were determined using the validated HPLC method described elsewhere (10, 27). Solutions were prepared three times. Results are expressed as mean ± SD.

The NS-1, NS-3, NS-5 and NS-9 micellar solutions were then spray-dried in the presence of leucine and mannitol (SD-2.5, SD-7.5, SD-12.5 and SD-22.5 formulations, respectively) using a Mini Spray Dryer B-290 (Büchi Laboratory-Techniques, Flawil, Switzerland) under the following conditions: spraying air flow 800 l/h; drying air flow 35 m3/h; solution feed rate 4.4 g/min; nozzle diameter 0.7 mm; inlet temperature 160°C, corresponding to an outlet temperature of ~69°C. The powders were blown though a high performance cyclone, collected in a container and stored in a desiccator at room temperature. Actual TMZ contents of the formulations were determined using the HPLC method. Results are expressed as mean ± SD (n=3). Theoretical compositions of SD-2.5, SD-7.5, SD-12.5 and SD-22.5 formulations after spray-drying and actual TMZ content are presented in Table II.

The ability of the SD-2.5, SD-7.5, SD-12.5 and SD-22.5 formulations to release the F-PEG-HMD nanomicelles in aqueous media was evaluated. Briefly, ~10 mg of dry powder was left to dissolve in 1.5 ml pH 5.0 phosphate buffer for 30 min under gentle rotational agitation. It was then vortexed using an L46 vortex (Labincov B.V., Breda, The Netherlands) twice for 60 sec and finally centrifuged (2,000 x g for 10 min). Particle size distribution of the supernatants was determined by means of a size exclusion chromatography (SEC) method.

The NS-1, NS-3, NS-5 and NS-9 micellar solutions were then spray-dried in the presence of leucine and mannitol (SD-2.5, SD-7.5, SD-12.5 and SD-22.5 formulations, respectively) using a Mini Spray Dryer B-290 (Büchi Laboratory-Techniques, Flawil, Switzerland) under the following conditions: spraying air flow 800 l/h; drying air flow 35 m3/h; solution feed rate 4.4 g/min; nozzle diameter 0.7 mm; inlet temperature 160°C, corresponding to an outlet temperature of ~69°C. The powders were blown though a high performance cyclone, collected in a container and stored in a desiccator at room temperature. Actual TMZ contents of the formulations were determined using the HPLC method. Results are expressed as mean ± SD (n=3). Theoretical compositions of SD-2.5, SD-7.5, SD-12.5 and SD-22.5 formulations after spray-drying and actual TMZ content are presented in Table II.

The ability of the SD-2.5, SD-7.5, SD-12.5 and SD-22.5 formulations to release the F-PEG-HMD nanomicelles in aqueous media was evaluated. Briefly, ~10 mg of dry powder was left to dissolve in 1.5 ml pH 5.0 phosphate buffer for 30 min under gentle rotational agitation. It was then vortexed using an L46 vortex (Labincov B.V., Breda, The Netherlands) twice for 60 sec and finally centrifuged (2,000 x g for 10 min). Particle size distribution of the supernatants was determined by means of a size exclusion chromatography (SEC) method.

**In vitro release kinetics of temozolomide.** The in vitro release kinetics of TMZ from the SD-2.5 and SD-7.5 dry powder formulations were determined in simulated lung fluid (SLF) (41), at pH 5.0 to guarantee the stability of TMZ, by an adapted dialysis method (42). The TMZ release from raw TMZ (median diameter of particle distribution (d(0.5)) = 21.3±0.4 µm) in the same conditions was used as a control for the method. Briefly, an amount of dry powder formulation corresponding to ~4 mg of TMZ was dispersed in 2 ml of SLF and placed in a dialysis membrane (MWCO = 10 kDa), then placed in 800 ml of SLF maintained at 37±1°C under magnetic agitation (200 rpm). The percentages of dissolved TMZ were determined by the HPLC method at different times up to 160 min. The 100% TMZ dissolution concentration corresponds to the TMZ concentration at 160 min (n=3).

**Cell culture.** Murine M109-HiFR lung carcinoma cell subline (43) was kindly provided by Dr Hilary Shmeeda from Shaare Zedek Medical Center (Jerusalem, Israel). It was cultured in folate-free RPMI supplemented with 10% FBS, 1% penicillin-streptomycin and 0.02% gentamycin in atmosphere containing 5% CO₂ at 37°C. Human A549 NSCLC cell line (from the American Type Culture Collection, Manassas, VA, USA; code CCL-185) was cultured in RPMI in the same conditions.

**In vitro anti-proliferative properties of the dry powders.** The anti-proliferative properties of the dry powders were determined by means of a colorimetric MTT assay (27,44,45) using two lung cancer cell lines (M109-HiFR and A549 cell lines). Briefly, cells were allowed to grow in a 96-well plate with a flat bottom with 20,000 or 1,100 cells/well of M109-HiFR or the A549 cell line, respectively. After a 24-h period of incubation at 37°C, the culture medium was replaced by folate-free RPMI containing a raw TMZ solution (positive control), formulation...
SD-2.5, formulation SD-7.5 or formulation SD-7.5 without TMZ (TMZ-free SD-7.5). The cells were incubated for 2 h with formulations and left to grow for 72 h in the appropriate supplemented medium. The TMZ-relative concentrations that were tested were $10^{-6}$ M, $5 \times 10^{-6}$ M, $10^{-5}$ M, $5 \times 10^{-5}$ M, $10^{-4}$ M, $5 \times 10^{-4}$ M, $10^{-3}$ M, $5 \times 10^{-3}$ M and $10^{-2}$ M. The test measures the number of metabolically active living cells that are able to reduce the yellow MTT to blue formazan by mitochondrial reduction. The amount of formazan obtained is directly proportional to the number of living cells. It was measured by spectrophotometry using a Bio-Rad 680XR spectrometer (Bio-Rad Laboratories, Nazareth, Belgium) at 570 nm (with a reference of 630 nm). The half maximal inhibitory concentrations (IC$_{50}$ values relative to TMZ) were defined as the TMZ concentrations that inhibit 50% of cells from growing, compared to the untreated control. The experiment was carried out once, in six replicates. Results are expressed as the mean ± SEM.

**Results**

**Synthesis and characterization of F-PEG-HMD.** F-PEG-HMD was successfully synthesized in three main steps using carbodiimide-mediated coupling chemistry: i) synthesis of HMD-succinate, ii) synthesis of F-PEG and iii) grafting of F-PEG on HMD-succinate. Carbodiimide derivatives, assisted by NHS and DmAP, allowed the formation of both amide linkage (i.e. synthesis of F-PEG) and ester linkage (i.e. synthesis of HMD-succinate and F-PEG-HMD). This carbodiimide-mediated coupling method was effective in both DmSo and water using DCC and eDC, respectively. The chemical structure of each intermediate (i.e. synthesis of HMD-succinate and F-PEG-HMD). This carbodiimide-mediated coupling method was effective in both DmSo and water using DCC and EDC, respectively. The chemical structure of each intermediate (i.e. synthesis of HMD-succinate and F-PEG-HMD). This carbodiimide-mediated coupling method was effective in both DmSo and water using DCC and EDC, respectively. The chemical structure of each intermediate (i.e. synthesis of HMD-succinate and F-PEG-HMD). This carbodiimide-mediated coupling method was effective in both DmSo and water using DCC and EDC, respectively.

Folate content was determined in F-PEG using UV spectroscopy. The folate content value in F-PEG was 0.26±0.01 mmol/g (98±5% of the theoretical value, 0.27 mmol/g).

The chemical structure of F-PEG-HMD is presented in Fig. 1A. F-PEG-HMD consists of an amphiphilic copolymer formed by a hydrophobic moiety, the grafted stearate chains and a hydrophilic moiety, the dextran polymer with which PEG chains are grafted. Once in the presence of aqueous media, F-PEG-HMD self-assembled as nanomicelles with a hydrophobic core composed of the stearate chains, a hydrophilic corona composed of dextran and PEG chains and folate moieties at the extremities of most of the PEG chains.

$^1$H NMR confirmed the successful synthesis and the chemical structure of F-PEG-HMD, with characteristic peaks at 0.9, 1.3 and 1.6 ppm for stearate chains, between 3.3 and 4.5 ppm for dextran polymer, at 3.7 ppm for PEG chains and at 6.9, 7.7 and 8.8 ppm for folate groups (Fig. 1C). Grafting of stearate and succinate groups on dextran chains was also confirmed by proton peaks between 4.9 and 5.2 ppm (i.e. using DmSO-d$_6$ as solvent). These peaks correspond to protons of esterified glucose monomers (i.e. the three protons on C2, C3 and C4). Residual non-esterified glucose monomers have characteristic peaks between 3.3 and 4.5 ppm. F-PEG-HMD is characterized by an ST-gR, SU-gR and Peg-gR of 3, 18 and 5%, respectively (Fig. 1D). Mass spectrometry also confirmed engraftment of the different parts of the copolymer F-PEG-HMD; the Mw range observed was from 36 to 50 kDa (Fig. 1D).

CMC (in a defined solvent) is an important characteristic of self-assembled copolymers because it relates to the stability of the micelles formed in a medium (24-26,46). Below this CMC, the copolymer will be present in the solvent as a solubilized single copolymer chain. However, once the CMC is reached, the copolymer chains will start to aggregate and self-assemble to form micelles, a structure that is thermodynamically more stable at this concentration. It is evident that below the CMC (i.e. after dilution of the copolymer in large physiologic media), the drug contained in the micelles will be released in the bulk medium. The CMC of F-PEG-HMD was determined in ultrapure water at 25°C by DLS; the CMC...
observed was 0.02 mg/ml or 4×10⁻⁷ M. This CMC is lower than that of most surfactants and is slightly lower than that of most lipopolymer conjugates, which are usually characterized by a CMC of up to 10⁻⁶ M (25), suggesting a good stability of the F-PEG-HMD-formed nanomicelles. In water at 25°C, the nanomicelles are characterized by a trimodal particle size distribution, with maximum particle diameter peaks at ~180, ~50 and ~10 nm, represented by a relative intensity of ~61, ~36 and ~2%, respectively (Fig. 1B). The Z-average and PdI observed was 83±1 nm and 0.46±0.01 (Table I), respectively. Such a polydispersed particle size distribution is possibly due to non-homogeneous grafting over the dextran backbone, a characteristic that is usually observed in grafted copolymers (26). The PEG and stearate chains are grafted randomly throughout the dextran chain; therefore, different aggregations can occur as well as different aggregation numbers (i.e. the number of copolymer chains involved in forming a micelle), resulting in different particle sizes. For example, in a certain conformation, hydrophobic stearate chains may be positioned close to the water, leading to a large particle size. In addition, depending on the stearate grafting, one copolymer chain may form a micelle itself, i.e. a micelle with an aggregation number of 1, resulting in a small particle size (26). The zeta potential observed was -16.8±0.2 mV.

Thermal analysis showed a thermal degradation of F-PEG-HMD characterized by a consequent loss of weight starting from ~150°C (loss of weight of 3% up to 200°C). DSC analysis showed an endothermic peak at 50°C, which corresponds to the melting of PEG and stearate chains (references given by the suppliers). It also showed a glass transition (T_g midpoint) at ~117°C, which was believed to correspond to the T_g of the dextran part (47).

**Preformulation investigation - micellar solubilization of TMZ.** In order to observe the ability of F-PEG-HMD nanomicelles to increase TMZ’s solubility in aqueous media, TMZ saturation solubility was determined in the absence or presence of 1, 5, 10, 15 and 20 mg/ml F-PEG-HMD (corresponding to mean molar concentrations of 0.023, 0.116, 0.232, 0.349 and 0.465 mM, respectively) in a phosphate buffer at room temperature. A phosphate buffer at pH 5.0 was used to guarantee the stability of TMZ. In addition to making a first approximate estimate of TMZ saturation solubility in physiologic media, the present study was carried out to produce dry powders with the highest TMZ loading from an initial TMZ/F-PEG-HMD solution. Fig. 2 shows the S_max observed for each tested C_mic. With regard to the data, F-PEG-HMD nanomicelles increase TMZ solubility in aqueous media to a maximum of a 2-fold increase in TMZ saturation solubility (~15 and ~30 mM in the absence or presence of 20 mg/ml F-PEG-HMD, respectively). This solubility increase appeared to be non-linear (Fig. 2) in the range of tested F-PEG-HMD concentrations. This result suggests a modification of the structure and/or aggregation of the nanomicelles. Two regression lines were drawn: the first for C_mic up to ~0.11 mM (R²=0.98) and the second for C_mic from ~0.11 to ~0.45 mM (R²=0.94), leading to two molar solubilization capacity values (k₁=79.56 and k₂=11.26). The results indicate that for low F-PEG-HTCC concentrations (less than ~0.11 mM), the capacity of the copolymer to solubilize is higher than for high concentrations (more than ~0.11 mM).

**Production of dry powders.** The dry powders were produced by spray-drying F-PEG-HMD/TMZ nanomicelle solutions. Nanomicelle solutions were first prepared by co-solubilization of 1, 3, 5 and 9 mg/ml F-PEG-HMD and the highest possible amount of soluble TMZ in phosphate buffer at pH 5.0 (Table I). In order to evaluate the influence of the presence of TMZ on the physicochemical properties of the nanomicelle solutions, two TMZ-free nanomicelle solutions were prepared: Empty NS-1 and Empty NS-9 were prepared using 1 and 9 mg/ml F-PEG-HMD, respectively. The composition and physicochemical properties of Empty NS-1, Empty NS-9, NS-1, NS-3, NS-5 and NS-9 are presented in Table I. All the prepared nanomicelle solutions were characterized in a buffer at pH 5.0 by trimodal particle size distribution. Regarding the Z-average values, the size of the nanomicelles slightly increased with the concentrations of F-PEG-HMD and TMZ (Z-average of 50±1 and 61±3 nm for the NS-1 and NS-9 solutions, respectively). This increase in size seems to be attributed only to the increase in the F-PEG-HMD concentration (and not to the presence of TMZ), from the similar size increase from Empty NS-1 and Empty NS-9 (Z-average of 56.8±0.8 and 68±1 nm, respectively). However, the presence of TMZ seems to have a weak influence on the particle size distribution of the nanomicelles. The size and the PdI of the TMZ-loaded micellar solutions were a little lower than for the TMZ-free nanomicelle solutions, which characterizes a more homogeneous particle population. This could be explained by the fact that TMZ could participate in the structure of the nanomicelles, for example as a hydrophilic corona and/or by causing a reduction in the number of aggregations of the nanomicelles, leading to a more homogeneous particle size distribution and/or smaller size. Regarding the EE values in Table I, TMZ was difficult to entrap within the F-PEG-HMD nanomicelles; the EE observed were <10% in any nanomicelle solution. This could easily be explained by the physicochemical properties of TMZ. TMZ is a small molecule that, besides having low solubility in water (~3 mg/ml), cannot be considered as a lipophilic compound (logP=1). Consequently, its encapsulation within a hydrophobic core such as that composed by stearate chains...
in the present nanomicelles represents a real challenge. The F-PEG-HMD concentration had no influence over the range of concentrations tested (EE = -9%) except for NS-1 (1 mg/ml F-PEG-HMD). For this, the EE observed was a little lower (~6%). The quite similar EE values observed from NS-3 to NS-9 also confirmed that TMZ does not induce an increase in size. The NS-1, NS-3, NS-5 and NS-9 nanomicelle solutions were then spray-dried to produce dry powders. Spray-drying a buffer containing only F-PEG-HMD and TMZ led to poor yield (~40%) and to production of a sticky powder (data not shown). As mentioned above, stearate and PEG chains melt at a temperature ~50°C, so spray-drying such low-melting compounds could lead to their partial melting. This issue was solved by adding hydrophilic carriers in solution, i.e., mannitol and leucine. Leucine has been widely employed as a component in DPI formulations for its ability to improve the dispersion properties of a dry powder (48-50). Different studies have shown that leucine allows the production of less cohesive particles due to its surfactant behavior (51). During the spray-drying process, leucine i) reduces the size of droplets, therefore ii) reduces the size of particles produced and iii) creates a coating around the dried particles (51). However, Kho and Hadinoto (52) observed that a single-carrier dry powder using leucine did not allow sufficient aqueous re-dispersibility of the initial nanomaterials. Leucine presents poor wettability properties that lead to poor re-dispersibility of nanomaterials (52). Therefore, mannitol was used in addition to leucine. Different proportions of F-PEG-HMD in the dry powders were tested, as presented in Table II. Production of all the dry powders led to yields between ~70 and ~85%. After initial optimization, 20% w/w leucine (relative to total dried materials) was the most appropriate concentration in terms of aerosolization and flowability properties (data not shown).

The actual TMZ contents in Table II revealed that production of the SD-2.5 and SD-7.5 led to more similar TMZ contents than expected. Conversely, for the SD-12.5 and SD-22.5 formulations, which contained the highest proportions of F-PEG-HMD, the actual TMZ contents observed were much lower than the theoretical TMZ contents. An explanation would be that the SD-12.5 and SD-22.5 formulations probably do not have enough additional excipient (i.e., mannitol and leucine) to avoid large losses of F-PEG-HMD (and TMZ by extension, due to TMZ/F-PEG-HMD micellization) on the glass assembly of the spray-dryer. These losses are due to partial melting of PEG and/or stearate chains during the spray-drying process. However, very similar yields were obtained for all spray-dried formulations. Another preferred explanation would be that the loss of TMZ is due to preferential accumulation of the nanomicelles at the surface of the dried particles, which is a well-known problem with spray-dried nanocomposites (53). This problem is due to an expected high Péclet number [i.e., a dimensionless mass-transport number that compares the times for droplet drying and the dispersed/dissolved particle diffusion (53,54)] for the drying droplets, which results from the relative low diffusion coefficient of the nanomicelles compared to solubilized mannitol and leucine. As the process involves spray-drying a micellar solution composed of TMZ and F-PEG-HMD, TMZ is probably attracted by the nanomicelles to the surface of the dried particles. As the surface of the dried materials contained higher proportions of TMZ/F-PEG-HMD in SD-12.5 and SD-22.5 than in SD-2.5 and SD-7.5, surface erosion during the spray-drying process led to much lower TMZ contents than expected.

The ability of the DPI formulations to release the F-PEG-HMD nanomicelles in aqueous media was evaluated. As described above, spray-drying involves high shear forces and an elevated temperature, which could induce irreversible aggregation of the spray-dried nanomicelles. In this case, dissolution of the DPI formulation in an aqueous media could lead to aggregated micelles with sizes >1 µm or even lead to insoluble residues. Once dissolved in the buffer, none of the DPI formulations led to visible insoluble residues (no sediment formation, even after centrifugation), except for the SD-22.5 formulation. The nanomicelles resulting from the SD-2.5, SD-7.5 and SD-12.5 formulations were characterized by quite similar trimodal particle size distributions. These had maximum peaks at ~10, ~75 and 470 nm, corresponding to relative intensities of ~5, ~35 and ~60%. The supernatant of the solution resulting from the SD-22.5 formulation presented larger nanomicelles than the three other DPI formulations (maximum peaks at ~25, ~141 and 712 nm, corresponding to relative intensities of ~3, ~50 and ~43%). These results indicate that nanomicelles aggregate during spray drying for each DPI formulation. However, this aggregation was reduced and considered as acceptable in SD-2.5, SD-7.5 and SD-12.5. This was because it still led to the formation of nanomicelles and no insoluble residues were observed after reconstitution in the buffer.

**Aerodynamic performance of the dry powders.** The aerodynamic diameter is the most appropriate measure of aerosol particle size because it relates to particle dynamic behavior and describes the main mechanisms of aerosol deposition in the lung as both gravitational settling and inertial impaction (55). Aerosol particles need to present aerodynamic diameters of between 1 and 5 µm to reach the lower respiratory tract. By presenting optimal aerodynamic diameters, inhaled particles should be able to reach lung tumors to deliver their pharmacological effects and thus their therapeutic benefits.

**In vitro** pulmonary deposition and FPF values for the SD-2.5, SD-7.5, SD-12.5 and SD-22.5 formulations are presented in Fig. 3. SD-2.5 showed the best aerodynamic profile. It had the highest deposition in stages 3-5, corresponding to cut-off aerodynamic diameters <5.27 µm at the flow rate of 100 l/min. Moreover, SD-2.5, and to lesser extent SD-7.5, led to a broad deposition, from the stages corresponding to the trachea to those illustrating the bronchioles and small terminal airways. In other words, SD-2.5 (and SD-7.5) might potentially be able to reach the lung tumor site(s) wherever it is located in the respiratory tract and might potentially lead to therapeutic benefits in lung cancer therapy. Conversely, SD-12.5 and especially SD-22.5 showed very poor aerodynamic properties, with a very low proportion of particles deposited in later stages (non-detectable values in stages 4 and 5; Fig. 3). They, therefore, cannot be considered as an inhalable dry powder. The **in vitro** pulmonary deposition profile revealed that SD-12.5 and SD-22.5 are mainly composed of large particles. More than 40-70%, respectively, of their particles were deposited...
in stage 1, which corresponds to the upper respiratory tract. Administration of one of these two formulations to a patient with a tumor located in the lower respiratory airway will lead inevitably to a treatment failure.

The proportion of F-PEG-HMD in the formulations had a direct influence on the aerodynamic properties of the dry powders: the smaller the proportion of F-PEG-HMD in the dry powders, the higher was the FPF (48±6 vs. 0% for SD-2.5 and SD-22.5, respectively). This could be explained by a partial melting of PEG and stearate chains in F-PEG-HMD (melting temperature, 50°C, see above) during spray drying (outlet temperature, 70°C), leading to large dried particles and large aerodynamic diameters (MMAD of 3.4±0.5, 4.4±0.4 and 5.82±0.08 µm for SD-2.5, SD-7.5 and SD-12.5, respectively).

Regarding the in vitro lung deposition profiles obtained, it was concluded that SD-2.5 and SD-7.5 presented the best characteristics for potentially having a therapeutic efficacy against lung cancers located in the lower respiratory tract. This affirmation will be confirmed by future in vivo evaluations. Consequently, these two formulations were selected to pursue in the study.

**In vitro release kinetics of TMZ.** The in vitro release kinetics of TMZ from formulations SD-2.5 and SD-7.5 were determined in simulated lung fluid (SLF) at 37°C and compared to the release from raw TMZ, which was used as a control. The release profiles are presented in Fig. 4.

The TMZ dissolution from raw TMZ, which is mainly dependent on the particle surface area [i.e. determined by the particle size distribution (d(0.5) = 21.3±0.4 µm)], was the fastest, with up to 77 and 90% dissolved within 20 and 30 min (significant different from formulations SD-2.5 and SD-7.5, P<0.05, 1-way ANOVA test with Dunnett's multiple comparison test). Despite the higher particle surface area of TMZ particles in the dry powder (i.e. due to their smaller size and the hydrophilic matrix composed of the mannitol) the TMZ release from the dry powders seemed to be slightly lower. Moreover, the presence of F-PEG-HMD in the powder formulations seemed to have a slight effect on the TMZ release in the SLF: the higher the proportion of F-PEG-HMD in the dry powder, the slower was the release (64±2, 67±4 and 77±2% released within 20 min for SD-2.5, SD-7.5 and raw TMZ, respectively). These results tend therefore to prove interactions between TMZ and F-PEG-HMD in physiologic medium. These interactions induce a slowdown of the TMZ release from the formulations, as compared to raw TMZ. However, there is an indubitable similarity between the three curves [similarity factor f2 (56) = 64 and 59 for raw TMZ and SD-2.5 and for raw TMZ and SD-7.5, respectively]. The interactions between TMZ and F-PEG-HMD in physiological media seemed to be therefore limited. The similarity of the dissolutions profiles might be explained by the physicochemical properties of TMZ leading to two main issues for its sustained release from the dry powders. The first is that TMZ, while being a poorly water-soluble compound (solubility of ~3 mg/ml in water), cannot be considered as a lipophilic compound (logP-value of ~1). These physicochemical properties lead to the dry powders containing a high proportion of free TMZ (low EE values
in Table I). This is a high proportion of TMZ that does not interact with F-PEG-HMD nanomicelles, and that is therefore free to dissolve and release from the formulations in the same way as from raw TMZ. Secondly, TMZ is probably present in a very high proportion in the nanomicelle corona (rather than in the nanomicelle core), which is characterized by a relative higher hydrophilicity than the micelle core. The outside TMZ will be released in the medium very quickly, as compared to the share of TMZ included inside the nanomicelle core.

**In vitro cytotoxic activity of the dry powders.** The *in vitro* anti-proliferative properties of the dry powder formulations were evaluated by means of colorimetric MTT assay and compared to a solution of raw TMZ as a positive control. This viability assay is used to verify that TMZ conserves its *in vitro* anti-proliferative properties inside the dry powder.

All the IC\textsubscript{50} values of the tested TMZ-based DPI formulations (Table III) were similar to raw TMZ for the two cell lines tested. These results proved that TMZ is still active inside the DPI formulations *in vitro* and remains stable during all the formulation steps. As presumed, formulation SD-7.5 without TMZ (Empty SD-7.5) led to a > IC\textsubscript{50} compared to the highest concentration tested, which confirmed a good tolerance of the DPI formulations.

### Discussion

DPI formulations composed of a new copolymer F-PEG-HMD were developed. The new copolymer F-PEG-HMD is able to self-assemble spontaneously in aqueous media as nanomicelles and can potentially interact with poorly water-soluble drugs, as is the case for most anticancer drugs. F-PEG-HMD is constituted of three main parts (Fig. 1): the loading compound, i.e. HMD, which should potentially be able to interact non-covalently with the drug; the targeting agent, i.e. the folate group; and the spacer, i.e. PEG, which should allow optimal interaction of the folate group and FR (to evaluate in future work). F-PEG-HMD nanomicelles should be at least as stable as most of the lipopolymer conjugates already described (24-26,46), considering its relatively low CMC value. High stability of the micelles after *in vivo* administration resulting from, among other characteristics, the CMC value is an important point to consider in order to guarantee their integrity (24,25). It is believed that the low volumes of lung fluids present in the respiratory tract [10-20 ml/100 m\textsuperscript{2} (57)] and the low CMC obtained for F-PEG-HMD should guarantee the micellar assembly of F-PEG-HMD after its administration as a dry powder by inhalation.

Although the physicochemical properties of TMZ make its encapsulation into nanovectors difficult (58), TMZ was chosen as cytotoxic drug model for this study due to its interesting anti-cancer properties in poor prognosis cancers such as glioblastoma and melanoma, as well as for lung cancer (31). We observed a non-negligible increase in TMZ solubility in water in the presence of F-PEG-HMD (2-fold increase of molar solubility in water). This increase in solubility could potentially lead to increased local concentrations in the tumor site after administration as a DPI. However, attention must be paid concerning the entrapment of TMZ within the F-PEG-HMD nanomicelles. A high proportion of TMZ contained in the dry powders is free to dissolve immediately in the medium. This ‘free TMZ’ proportion corresponds to i) non-entrapped TMZ and ii) adsorbed TMZ on the corona of the nanomicelles. Indeed, as previously described, TMZ is characterized as amphiphilic by nature and so TMZ should locate preferentially in the corona of nanomicelles. However, despite the probably low proportion of TMZ inside the core of the nanomicelles, we observed small differences in the release of TMZ from raw TMZ and dry powder formulations (Fig. 4).

The main dissolution-limiting factor of raw TMZ is the particle surface area, determined by the particle size distribution (d(0.5)=21.3±0.4 µm). However, the main dissolution-limiting factors of TMZ from dry powder are: i) the particle surface area of the particles presenting a ‘free TMZ’ proportion on their surface, ii) the re-dispersibility of the nanomicelles from the dry powder and iii) the diffusion rate of TMZ from the nanomicelle corona (i.e. depending on the interactions between TMZ and F-PEG-HMD). The particle surface area of particles presenting a ‘free TMZ’ proportion on their surface in the dry powder should be higher (i.e. than raw TMZ particles) due to their smaller size. Moreover, the hydrophilic matrix composed of the mannitol and leucine allows a quick re-dispersibility of the nanomicelles, causing a considerable increase in the surface area (see aqueous re-dispersibility of the nanomicelles).

Despite these two factors tending to increase the TMZ release from the dry powders, the TMZ release from the dry powders seems to be slightly lower. This is certainly due to the share of TMZ entrapped in the nanomicelle corona. TMZ is present in the powders with F-PEG-HMD, which should potentially be able to recognize the overexpressed FRs on the targeted lung tumor cells due to the grafted folate groups on the PEG extremities. Thus, once inhaled and deposited in the lung as shown *in vitro* by the acceptable FPF of the DPI formulations, the additional hydrophilic excipients, i.e. mannitol and leucine, dissolve quickly and rapidly release nanomicelles from the dry powders. This is shown *in vitro* by the recovery of the nanomicelles from the DPI formulations in water. This quick recovery therefore might permit the interaction between the folate groups and the FRs.

Another issue encountered with TMZ is the difficulty of evaluating its cytotoxic activity *in vitro*. TMZ is characterized by weak *in vitro* cytotoxic activity compared to other anticancer drugs, such as cisplatin (59). An *in vitro* evaluation of its anticancer activity is therefore in no way representative of the potent *in vivo* activity of TMZ against lung cancers. As an example, Mathieu *et al* (59) observed that TMZ had no

<table>
<thead>
<tr>
<th>Formulations</th>
<th>M109-HiFR lung carcinoma</th>
<th>A549 NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raw TMZ</td>
<td>6.0±0.2</td>
<td>3.15±0.08</td>
</tr>
<tr>
<td>SD-2.5</td>
<td>5.9±0.1</td>
<td>3.3±0.1</td>
</tr>
<tr>
<td>SD-7.5</td>
<td>4.0±0.1</td>
<td>2.8±0.2</td>
</tr>
</tbody>
</table>

Results are expressed as mean ± SEM values (n=6).
significant in vitro inhibitory effect on different melanoma cell lines (such as the mice B16F10 melanoma) at concentrations up to 10 μM, although it displayed interesting in vivo activity on B16F10 mouse melanomas. As expected, IC$_{50}$ values in Table III confirmed the quite high IC$_{50}$ values (in the milli-molar range), as reported in the literature (59,60).

The present study showed that it is possible to formulate dry powder for inhalation composed of a new self-assembling copolymer, F-PEG-HMD, and a cytotoxic drug, in this case TMZ. The developed DPI formulations are characterized by good aerodynamic properties and are able to release the nanomicelles quickly in aqueous media. This is especially true for the SD-2.5 and SD-7.5 formulations, which are characterized by FPPs of up to 50%. These two DPI formulations showed broad deposition in the impinger and should lead to a broad deposition in the lower respiratory tract, where adenocarcinomas are most frequently found. Assuming that F-PEG-HMD nanomicelles should recognize the lung adenocarcinoma cells though the overexpressed FRs (to be evaluated in future work), we can therefore conclude that F-PEG-HMD-based dry powders for inhalation could be an interesting drug delivery system that is able to release nanomicelles useful against adenocarcinomas that overexpress FRs. Future studies will evaluate our new F-PEG-HMD-based dry powder formulations. These formulations will be loaded with other anticancer drugs characterized by a higher lipophilicity than TMZ to allow drug encapsulation inside the core of the F-PEG-HMD nanomicelles.

Acknowledgements

Rémi Rosière was supported by a grant from the FRiA-FNRS (Fonds National de la Recherche Scientifique, Belgium). The analytical platform is supported by grants from the FRS-FNRS (Fonds de la Recherche Scientifique), no. 34553.08, and a grant from the FER 2007 (Fonds d’Encouragement à la Recherche, ULB).

References


